The First International Symposium on Haemopoietic Stem ere aplastic anaemia considered, at least in part, as an autoimmune disease. Most transplants were performed on Cell Therapy in Autoimmune Diseases took place in Basel on 26-28 September 1996 . This 2 day meeting gathered patients with an autoimmune disease and concomitant or underlying haematological disorder, eg gold-induced severe around 250 people (30 of whom were invited speakers or chairmen) about half of whom were involved in aplastic anaemia in patients with rheumatoid arthritis or autoimmune diseases in patients with leukaemia. A single rheumatology/immunology and the other half in haematology/oncology. case of relapse of rheumatoid arthritis following allogeneic BMT has been reported where the immune cells were of donor origin. The major risk of allogeneic BMT is occurrence of graft-versus-host disease and its associated risk Background of mortality. The current concept views autoimmune disease (AD) as a consequence of disturbed and altered immune response leading to an attack by the immune system against host Autologous transplants antigens. The reaction is polyclonal and contains B and T cell components. The basic mechanisms are still poorly Present patient data are still anecdotal, heterogenous and understood. However, once established, the disease process with a limited follow-up. They show that sufficient stem usually continues and leads to tissue destruction and somecells can be collected to repopulate the haemopoietic systimes death.
tem following ablative therapy when techniques are used All cells of the immune system are derived from the as in the treatment of haematological malignancies. It is haemopoietic stem cell. As in the case of the monoclonal too early to know whether in autoimmune diseases toxicity origin of haematological malignancies, it is unknown is different or whether long lasting remissions can be whether the true stem cell itself is affected or only its obtained. progeny. Experimental data in animals clearly show that
The following recommendations can be made based on some diseases can be cured by allogeneic transplants from available data. healthy, non-affected, major histocompatibility complex compatible donors and also by autologous transplants.
General

Clinical evidence
Allogeneic transplants
In patients with a disorder such as leukaemia which would normally be treated with BMT, the presence of a concomiThere is clinical evidence that allogeneic bone marrow tant AD should not be considered as a contraindication to transplantation (BMT) can lead to long lasting remission BMT, but rather a potential added bonus. In the absence and eventually cure. Greatest experience is available in sevof haematological disorders, blood and marrow transplantation in autoimmune disease should be viewed as an experimental procedure to be carried out only after infor- of the treatment protocol.
Donor type Haematological diseases
Syngeneic (identical twin) transplants would be ideal treat-(1) Severe refractory autoimmune thrombopenia. ment if an unaffected donor is available (rare).
(2) Autoimmune hemolytic anaemia. Autologous BMT in general preferred due to safety pro-(3) Immune neutropenia. file (3-5% mortality) and current experience; age limit 65 (4) Combinations thereof. years. Allogeneic sibling donor transplants can be considered if an HLA-identical sibling donor is available and if the risks Other conditions for consideration of disease exceed the risks involved in an allogeneic transplant (15-35% mortality). Since transplant-related mortality increases with age, patients should be considered for an
(1) Inflammatory bowel disease, eg Crohns. allogeneic blood or marrow transplant up to the age of 55 (2) Autoimmune diabetes mellitus. years. Until the benefits of the procedure are more clearly defined, unrelated volunteer donor transplants are not recommended.
Source of transplant
Theoretically, marrow or peripheral blood stem cells can be Disease indication used. Since it has been clearly documented that autologous peripheral blood stem cells lead to a faster and more comIn principle, only diseases severe enough to have an increased risk of mortality should be considered. Transplete recovery, peripheral blood stem cells are preferred to bone marrow-derived stem cells for autologous transplants. plants should be undertaken before irreversible organ damage has taken place such that significant clinical benefit However, bone marrow derived stem cells contain fewer mature autoreactive T cells which may prove to be can be achieved.
important if purging techniques fail to remove enough such cells. More data are required on this issue.
Rheumatological disorders
(1) Systemic sclerosis (scleroderma).
Mobilisation of stem cells for autologous transplants (2) Autoimmune pulmonary hypertension (after adequate trial of immunosuppression).
Available data do not suggest that reults of mobilisation (3) Necrotising vasculitis (following induction with stanwith haematological growth factors in patients with autodard immunosuppression).
immune diseases are different from mobilisation in patients (4) Rheumatoid arthritis (RA) with severe complications with haematological malignancies or solid tumours. eg necrotising vasculitis, scleritis.
Standardized approaches involve mobilisation with G-(5) RA, poor prognosis, rapidly progressive and destruc-CSF alone at a dose of 10 g/kg per day subcutaneously tive, resistant to adequate treatment.
once daily or following a priming dose of cyclophospham-• Bu/Cy regimen preferred in RA (Bu is radiomimetic ide 4 g/m 2 once. and possibly more effective against memory cells.)
Mobilisation and stem cell collection should only be perCy alone not excluded.
formed by approved haemato-oncological teams experi-(6) Systemic lupus erythematosis (SLE) -major organ enced in the collection of haemopoietic stem cells. The tarthreat, failed conventional therapy.
get cell dose for reinfusion should be Ͼ2 × 10 6 CD34 (7) Antiphospholipid antibody syndrome. positive cells per kg or Ͼ2 × 10 4 CFU-GM/kg. If manipu-(8) Severe, uncontrollable cryoglobulinaemia. lation ex vivo is planned, Ͼ3 × 10 6 CD 34 positive cells (9) Paediatric rheumatology: will need to be harvested.
• systemic sclerosis variants with pulmonary fibrosis • severe dermatomyositis (especially with pulmonary fibrosis) • severe necrotising vasculitis Manipulation of the graft NOT juvenile arthritis at this stage
Autoimmune diseases have both B and T cell components
Neurological disorders
and it is possible that T or B cells in the graft contribute to relapse of the disease and failure of the blood and marrow (1) Multiple sclerosis -conditioning with either:
(a) drugs which cross the blood/brain barrier (eg transplant as they do in haematological malignancies. Animal data suggest that this could be the case as do some busulphan) or (b) TBI -caution is necessary since in rats with EAE early anecdotal human case reports. Therefore, T cell purging is recommended aiming to transplant Ͻ1 × 10 5 cells/kg (experimental allergic encephalomyelitis) exacerbations are seen. Glucocorticoid cover may be of body weight of cells. If T or B cells are removed, the number of transplant CD34-positive cells, T cells and B cells benefit in humans.
(2) Myasthenia gravis.
as well as the methods employed should be recorded. globulin may or may not be added.
Harwood Academic: Reading, UK, 1996, pp 441-450.
(2) Cyclophosphamide 60 mg/kg for 2 days at 1-h i.v. 
